Stockreport

NewAmsterdam Pharma Reports Full Year 2023 Financial Results and Provides Corporate Update

NewAmsterdam Pharma Company N.V. - Ordinary Shares  (NAMS) 
PDF -- On-track to report topline data from Phase 3 BROOKLYN trial in HeFH in 3Q 2024 and Phase 3 BROADWAY trial in ASCVD in 4Q 2024 -- -- Plan to initiate TANDEM, pivotal [Read more]